p 50%, indicating no heterogeneity, low heterogeneity, moderate heterogeneity, and substantial heterogeneity, respectively
Les tudes de cytotoxicit in vitro confirment l'absence de toxicit cellulaire aux concentrations physiologiques et supraphysiologiques
Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: what can we learn from transgenic and knockout mice
Food and Drug Administration: "QSYMIA (Phentermine and Topiramate Extended-Release Capsules), for Oral Use, CIV Label" University of California in San Francisco: "Are the New Weight Loss Drugs Too Good to Be True?" Journal of Health, Population and Nutrition : "What Could Be the Reasons for Not Losing Weight Even After Following a Weight Loss Program?" Obesity : "Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)" The Lancet : "Effects of Low-Dose, Controlled-Release, Phentermine Plus Topiramate Combination on Weight and Associated Comorbidities in Overweight and Obese Adults (CONQUER): A Randomised, Placebo-Controlled, Phase 3 Trial" Cleveland Clinic: "Why Losing 10 Pounds in a Month Isn't the Right Goal" Qsymia: "Risk of Birth Defects With Qsymia" Adam Gilden, MD, MSCE Medical Reviewer Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Me
